

**EXHIBIT 6-d to PLAINTIFFS'
APPENDIX OF EXPERT REPORTS**

Schedule 3. Materials Considered:

Complaint

Corrected Joint and Third Amended Complaint, *In re National Prescription Opiate Litigation as it relates to Cabell County Commission and City of Huntington, West Virginia*, Case No. 1:17-op-45053-DAP (S.D. W.Va.) and Case No. 1:17-op-45054 (S.D. W.Va.), in the United States District Court for the Northern District of Ohio, Eastern Division, September 16, 2019.

Expert Reports:

Expert Report of Kathleen Keyes

Expert Report of Jakki Mohr

Expert Report of Lacy Keller

Expert Report of Craig McCann

Expert Report of James Rafalski

Articles:

Africa, T., The Opium Addiction of Marcus Aurelius, 22 J. Hist. Ideas 97-102 (1961)

Angres DH, Bettinardi-Angres K. 2008. The disease of addiction: origins, treatment, and recovery. Dis. Mon. 54:696–721

Angst MS, Clark JD. 2006. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104:570–87.

Aron J. Hall, DVM, MSPH, et al., Patterns of Abuse Among Unintentional Pharmaceutical Overdose Fatalities, Vol. 300 No. 22, JAMA, 2613, 2619 (2008)

Arria AM, et al. (2008). Perceived harmfulness predicts nonmedical use of prescription drugs among college students: interactions with sensation-seeking. *Prev. Sci.*, 9(3), 191–201. doi: 10.1007/s11121-008-0095-8

Blair T. 1919. Is opium the “sheet-anchor of treatment”? Am. J. Clin. Med. 26:829–34; Rayport M. Experience in the management of patients medically addicted to narcotics. J Am Med Assoc. 1954;156(7):684-691

Boscarino JA, et al. (2011). Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 versus DSM-4 diagnostic criteria. *J. Addict. Dis.*, 30(3), 185–94. DOI: 10.1080/10550887.2011.581961

Boscarino JA, et al. (2010). Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. *Addiction*, 105(10), 1776–82. doi: 10.1111/j.1360-0443.2010.03052.x

Boscarino JA, Hoffman SN, Han JJ. (2015). Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates. *Subst Abuse Rehabil.*, 6, 83-91. doi: 10.2147/SAR.S85667

Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. *JAMA Psychiatry*. 2014;71(7):821-826

Compton WM, Jones CM, Baldwin GT. (2016). Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. *N Engl J Med.*, 374, 154-163.doi:10.1056/NEJMra1508490

Coyle MG, et al. (2012). Neonatal neurobehavior effects following buprenorphine versus methadone exposure. *Addiction*, 107(1), 63–73. doi: 10.1111/j.1360-0443.2012.04040.x

Davis CS, et al. (2014). Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. *Am. J. Public Health*, 104(8), e7–9. doi: 10.2105/AJPH.2014.302062

Des Jarlais DC, et al. (2005). HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. *Am. J. Public Health*, 95(8), 1439–44. doi: 10.2105/AJPH.2003.036517

Digiusto E, et al. (2004). Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence. *Addiction*, 99(4), 450–60. doi: 10.1111/j.1360-0443.2004.00654.x

Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. *Ann Intern Med* 2010;152:85–92

Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. *Clin J Pain*. 2014 Jul;30(7):557-64

Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. *Drug Alcohol Depend*. 2018;193:14-20

Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. 2006. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. *Pain* 125:172–79; Sullivan MD, Von Korff M, Banta-Green C, Merrill

Fishbain DA, Cole B, Lewis J, RosomoffHL, Rosomoff RS. 2008. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. *Pain Med*. 9:444–59; Juurlink DN, Dhalla IA. 2012

Fudala PJ, et al. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *N. Engl. J. Med.*, 349(10), 949–58. doi: 10.1056/NEJMoa022164

Gaither JR, Leventhal JM, Ryan SA, et al. National Trends in Hospitalizations for Opioid Poisonings Among Children and Adolescents, 1997 to 2012. *JAMA Pediatrics*. 2016;170(12):1195-1201

Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. 2012. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. *JAMA* 307:1934–40

Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. *Pharmacoepidemiol Drug Saf*. 2006;15(9):618-627

Paulozzi LJ. 2010. The epidemiology of drug overdoses in the United States. Grand Rounds Lecture Presented at Maimonides Med. Cent. Dep. Psychiatry, Brooklyn, New York

Paulozzi LJ. 2010. The epidemiology of drug overdoses in the United States. Presented at Promis. Leg. Responses to the Epidemic of Prescr. Drug Overdoses in the U.S., Maimonides Med. Cent. Dep. Psychiatry, Dec. 2, Grand Rounds, Brooklyn

Perry S, Heidrich G. 1982. Management of pain during debridement: a survey of U.S. burn units. *Pain* 13:267–80; Porter J, Jick H. 1980. Addiction rare in patients treated with narcotics. *N. Engl. J. Med.* 302:123

Williams AV, Marsden J, Strang J. (2014). Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes. *Addiction*, 109(2), 250–59. doi: 10.1111/add.12360

Seal KH, et al. (2005). Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. *J. Urban Health*, 82(2), 303–11. doi: 10.1093/jurban/jti053

Hagan H., et al. (2010). Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. *J. Infect. Dis*, 201(3), 378–85. doi: 10.1086/649783

McCarthy JJ, Leamon MH, Parr MS, Anania B. (2005). High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. *Am. J. Obstet. Gynecol.*, 193, 606–10. doi: 10.1016/j.ajog.2005.03.072

Jones HE, et al. (2010). Neonatal abstinence syndrome after methadone or buprenorphine exposure. *N. Engl. J. Med.* 363, 2320–31. DOI: 10.1056/NEJMoa1005359

Johnson RE, et al. (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. *N. Engl. J. Med.* 343(18), 1290–97. doi: 10.1056/NEJM200011023431802

KL, et al. (2000). Methadone maintenance for opioid dependence. *JAMA* 284(6), 694–95.

Strain EC, et al. (1999). Moderate versus high-dose methadone in the treatment of opioid dependence: a randomized trial. *JAMA*, 281(11), 1000–5. doi: 10.1001/jama.281.11.1000

Reif S, et al. (2014). Residential treatment for individuals with substance use disorders: assessing the evidence. *Psychiatr. Serv.* 65(3), 301–12. doi: 10.1176/appi.ps.201300242

Jones CM, et al. (2014). Sources of prescription opioid pain relievers by frequency of past-year nonmedical use: United States, 2008–2011. *JAMA Intern. Med.*, 174(5), 802–3. doi:10.1001/jamainternmed.2013.12809

Johnston LD, et al. (2014). Monitoring the future National Survey Results on Drug Use: 1975–2013. Overview, key findings on adolescent drug use. Ann Arbor, MI: Inst. Soc. Res., Univ. Mich.

Kattan JA, Tuazon E, Paone D, et al. (2016). Public Health Detailing-A Successful Strategy to Promote Judicious Opioid Analgesic Prescribing. *Am J Public Health*, 106(8), 1430-1438. doi: 10.2105/AJPH.2016.303274

Thomson MW, et al. (2006). Xerostomia and medications among 32-year-olds. *Acta. Odontol. Scand*, 64(4), 249–54. doi: [10.1080/00016350600633243](https://doi.org/10.1080/00016350600633243)

Tuteja AK, et al. (2010). Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. *Neurogastroenterol. Motil*, 22(4), 424–30. doi: 10.1111/j.1365-2982.2009.01458.x.

Vuong C, et al. (2010). The effects of opioids and opioid analogs on animal and human endocrine systems. *Endocr. Rev*, 31(1), 98–132. doi: 10.1210/er.2009-0009

Takkouche B, et al. (2007). Psychotropic medications and the risk of fracture: a meta-analysis. *Drug Saf.* 30(2), 171–84. doi: 10.2165/00002018-200730020-00006

Saunders KW, et al. (2010). Relationship of opioid use and dosage levels to fractures in older chronic pain patients. *J. Gen. Intern. Med.* 25(4), 310–15. doi: 10.1007/s11606-009-1218-z

Martell BA, et al. (2007). Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. *Ann. Intern. Med.*, 146(2), 116–27. doi: 10.7326/0003-4819-146-2-200701160-00000

Merwin, Samuel. Drugging a Nation: the Story of China and the Opium Curse, A Personal Investigation During an Extended Tour of the Present Conditions of the Opium Trade in China and Its Effects Upon the Nation (NY: F. H. Revell Co. 1908)

Sapira, J.D. (1975). Speculations concerning Opium Abuse and World History. *Perspectives in Biology and Medicine*, 18(3), 379-398

Nat'l Acads. of Science, Eng'g and Medicine, *Pain Mgmt. and the Opioid Epidemic*, National Academies Press (2017) at 17 (citing Rose Rudd, et al,(2016). Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015, *MMWR Morb Mortal Wkly Rep*, 65 (50-51), 1445-52. DOI: <http://dx.doi.org/10.15585/mmwr.mm655051e1>

Landsman-Blumberg PB, et al. (2017). Health care resource use and cost differences by opioid therapy type among chronic noncancer pain patients. *J Pain Res*, 10,1713-1722. doi: 10.2147/JPR.S130913

Van Zee, A. (2009). The promotion and marketing of OxyContin: Commercial triumph, public health tragedy. *Am J of Public Health*, 99(2), 221-227. doi: 10.2105/AJPH.2007.131714

Inciardi JA, et al., Prescription Opioid Abuse and Diversion in an Urban Community: The Results of an Ultra-Rapid Assessment. *Pain Medicine*. 10(3), 537-548, at 544. doi: 10.1111/j.1526-4637.2009.00603.x

"Every 'Never' I Ever Said Came True": Transitions from opioid pills to heroin injecting, Sarah G. Mars, Philippe Bourgois, George Karandinos, Fernando Montero, Daniel Ciccarone, Int J Drug Policy. Author manuscript; available in PMC 2015 Mar 1. Published in final edited form as: Int J Drug Policy. 2014 Mar; 25(2): 257–266. Published online 2013 Oct 19. doi: 10.1016/j.drugpo.2013.10.004

Initiation into prescription opioid misuse amongst young injection drug users. *Int J Drug Policy*, 23(1), 37-44, at 41. doi: 10.1016/j.drugpo.2011.05.014

JO, Saunders K. 2010. Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. *Pain* 149:345–53

Jones CM. 2013. Trends in the distribution of selected opioids by state, US, 1999–2011. Presented at Natl.

Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. *Annu Rev Public Health*. 2015;36:559-574

LeResche L, Saunders K, Dublin S, et al. Sex and Age Differences in Global Pain Status Among Patients Using Opioids Long Term for Chronic Noncancer Pain. *J Womens Health (Larchmt)*. 2015;24(8):629-635

Martin BC, Fan MY, Edlund MJ, Devries A, Braden JB, Sullivan MD. Long-term chronic opioid therapy discontinuation rates from the TROUP study. *J Gen Intern Med*. 2011;26(12):1450-1457

Martin WR, Jasinski DR. Physiological parameters of morphine dependence in man--tolerance, early abstinence, protracted abstinence. *J Psychiatr Res*. 1969;7(1):9-17

Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. *Arch Intern Med* 2011;171:686–91

Haddox JD, Joranson D, Angarola RT, Brady A, Carr DB, et al. 1997. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. *Clin. J. Pain* 13:6–8

Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. *Neuropsychopharmacology*. 2008;33(5):1179-1191

Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerdá M. Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses [published correction appears in JAMA Netw Open. 2019 Mar 1;2(3):e191625]. *JAMA Netw Open*. 2019;2(1):e186007. Published 2019 Jan 4. doi:10.1001/jamanetworkopen.2018.6007

Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, et al. 2008. Patterns of abuse among unintentional pharmaceutical overdose fatalities. *JAMA* 300:2613–20

Han B, Compton WM, Blanco C, et al. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. *Ann Intern Med.* 2017;167(5)

Hollander MAG, Donohue JM, Stein BD, Krans EE, Jarlenski MP. Association between Opioid Prescribing in Medicare and Pharmaceutical Company Gifts by Physician Specialty [published online ahead of print, 2019 Dec 2]. *J Gen Intern Med.* 2019;10.1007/s11606-019-05470-0. doi:10.1007/s11606-019-05470-0

Strickland JC, Havens JR, Stoops WW. A nationally representative analysis of "twin epidemics": Rising rates of methamphetamine use among persons who use opioids. *Drug Alcohol Depend.* 2019;204:107592

Hser YI, Hoffman V, Grella CE, Anglin MD. 2001. A 33-year follow-up of narcotics addicts. *Arch. Gen. Psychiatry* 58:503–8

Naliboff BD, Wu SM, Schieffer B, et al. A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. *J Pain* 2011;12:288–96

B. Meier, "In Guilty Plea, OxyContin Maker to Pay \$600 Million," *NY Times*, May 10, 2007 at <https://www.nytimes.com/2007/05/10/business/11drug-web.html>

Baldini A, Von Korff M, Lin EHB. A review of potential adverse effects of long-term opioid therapy: A practitioner's guide. *Prim Care Companion CNS Disord* 2012;14:pii

Baldwin, Grant. Overview of the Public Health Burden of Prescription Drug and Heroin Overdoses. CDC Presentation at FDA meeting. July 1, 2015. Available at <https://www.fda.gov/media/93249/download>. Accessed on July 29, 2020

Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. *JAMA* 2011;305:1315–21

Krueger AB. Where have all the workers gone? An inquiry into the decline of the US labor force participation rate. *Brookings Papers on Economic Activity Conference draft*. https://www.brookings.edu/wp-content/uploads/2017/09/1_krueger.pdf. Published August 26, 2017. Accessed April 21, 2020

Lynch S, Sherman L, Snyder SM, Mattson M. Trends in infants reported to child welfare with neonatal abstinence syndrome (NAS). *Child Youth Serv Rev.* 2018;86(C):135-141

O'Donnell JK, Gladden RM, Seth P. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region—United States, 2006-2015. *MMWR Morb Mortal Wkly Rep.* 2017;66(34):897-903

Paquette CE, Pollini RA. Injection drug use, HIV/HCV, and related services in nonurban areas of the United States: a systematic review. *Drug Alcohol Depend.* 2018;188:239-250

Johnson EM, Lanier WA, Merrill RM, Crook J, Porucznik CA, et al. 2013. Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008–2009. *J. Gen. Intern. Med.* 28:522–29

Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *JAMA*. 2016;315(15):1624-1645

Dowell D, Kunins HV, Farley TA. Opioid Analgesics—Risky Drugs, Not Risky Patients. *JAMA*. 2013;309(21):2219–2220. doi:10.1001/jama.2013.5794

Portenoy RK, Foley KM. 1986. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. *Pain* 25:171–86

Upadhyay J, Maleki N, Potter J, Elman I, Rudrauf D, et al. 2010. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. *Brain* 133:2098–114; Younger JW, Chu LF, D'Arcy NT, Trott KE, Jastrzab LE, Mackey SC. 2011. Prescription opioid analgesics rapidly change the human brain. *Pain* 152:1803–10

Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. *Pain Med* 2014;15:1911–29

"A drug challenge," Intelligencer Journal (Lancaster, PA.); Scott Finn and Tara Tuckwiller, The Killer Cure: Deaths tied to methadone escalate across state, nation, CHARLESTON GAZETTE-MAIL, June 4, 2006, https://www.wvgazettemail.com/news/special_reports/deaths-tied-tomethadone-escalate-across-state-nation/article_9a021a7d-b1f8-5f50-9711-17a5c9b182f7.html

N.Y. City Dep. Health Ment. Hyg. 2013. New York City Emergency Department Discharge Opioid Prescribing Guidelines. Long Island City, NY: NYC Health Available at <http://www.nyc.gov/html/doh/downloads/pdf/basas/opioid-prescribing-guidelines.pdf>

Pear R. Lobbying Effort Is Said to Sink New Controls on Painkillers. *New York Times*. June 18, 2012.; ENDO-OPIOID_MDL-02301476; HDA_MDL_000020031 at 035 *Minutes of the HDMA Executive Committee Meeting, June 10, 2012)

Lurie J. Big Pharma Has a Big Role on the Federal Committee Tasked With Curbing Opioid Abuse. May 19, 2019

Perrone, M. et al. (2016): Pro-painkiller echo chamber shaped policy amid drug epidemic. <https://publicintegrity.org/state-politics/pro-painkiller-echo-chamber-shaped-policy-amid-drug-epidemic/>

Transcript of the Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM), July 23, 2010 12, 8:00 a.m. to 3:30 p.m.

Gottlieb S. *The DEA's War on Pharmacies-and Pain Patients*. Wall Street Journal. March 22, 2012, available at <https://www.wsj.com/articles/SB10001424052702304636404577297332734154326>

Armstrong D. Inside Purdue Pharma's Media Playbook: How It Planted the Opioid "Anti-Story": OxyContin's makers delayed the reckoning for their role in the opioid crisis by funding think tanks, placing friendly experts on leading outlets, and deterring or challenging negative coverage. Propublica Nov. 19, 2019

Meir B. 2003. Pain Killer: A "Wonder" Drug's Trail of Addiction and Death. Rodale Inc.

[McKesson Website, "Opioid Abuse – Fighting the Epidemic." available at https://www.mckesson.com/About-McKesson/Fighting-Opioid-Abuse/](https://www.mckesson.com/About-McKesson/Fighting-Opioid-Abuse/)

McKesson Announces Settlement with DEA, Press Release. Businesswire. (May 2, 2008), available at, <https://www.businesswire.com/news/home/20080502005690/en/McKesson-Announces-Settlement-DEA>

<https://www.justice.gov/usao-ma/victim-and-witness-assistance-program/united-states-v-michael-babich-alec-burlakoff-richard-simon-sunrise-lee-joseph-rowan-and>

How Obama Plans To Combat Prescription Opioid And Heroin Abuse In 2016. Forbes, Feb 6, 2015.

How Should the U.S. Regulate Powerful Painkillers? PBS NewsHour, Jan 6, 2015.

"Groups unite against curbing painkillers. Boston Globe. Dec 29, 2014.

Opioids prescribed by doctors led to 92,000 overdoses in ERs in one year. LA Times, Oct 27, 2014.

Overdose deaths spur families to march on Mall over opioid epidemic. Washington Post, Sep 28, 2014.

Heroin's Death Toll Rising in New York, Amid a Shift in Who Uses It. New York Times, Aug, 28, 2014.

"Painkiller Paradox: Feds Struggle To Control Drugs That Help And Harm. NPR, Jan 23, 2012.

Rising Painkiller Addiction Shows Damage From Drugmakers' Role in Shaping Medical Opinion. Washington Post, Dec 30, 2012.

Prescription for Addiction. Wall Street Journal, Oct 5, 2012.

Lobbying Effort Said to sink New Controls on Painkillers. New York Times, Jun 19, 2012.

Senate Inquiry Into Painkiller Makers' Ties. New York Times, May 9, 2012.

U.S. Consumes 80% of World's Oxycodone. Newsday, Jan 21, 2012.

OxyContin: Purdue Pharma's Painful Medicine. Fortune Magazine, Nov 9, 2011.

Champion of Painkillers." Washington Post, Dec 23, 2011.

White House Plan to Target Painkiller Abuse. ABC News, Apr 25, 2011.

<https://wvbom.wv.gov/public/search/index.asp>

Complaint. West Virginia Board of Osteopathy v. Anita Dawson, Complaint No. 10-05, *available at*, https://www.justice.gov/archive/usao/wvs/press_releases/June2012/attachments/DawsonChargesSuspension.pdf

"Cabell County Doctor Sentenced to Two Years in Prison for Federal Drug Crime." *FBI, Pittsburgh Division.* 7 January, 2013. <https://archives.fbi.gov/archives/pittsburgh/press-releases/2013/cabell-county-doctor-sentenced-to-two-years-in-prison-for-federal-drug-crime>

<https://www.claimsjournal.com/news/southeast/2005/07/05/56882.htm>

https://www.herald-dispatch.com/_recent_news/more-than-65-million-opioids-flooded-cabell-county-over-7-years-data-shows/article_8f0d8676-a9a9-11e9-98ff-ebdd2586af3f.html

"Patient Adherence Solutions." Cardinal Website, *available at*, <https://www.cardinalhealth.com/en/services/manufacturer/biopharmaceutical/patient-access-and-adherence/patient-adherence-solutions.html>

McKesson Health Solutions. *InterQual Connect™ Enable automation of authorizations requiring medical review, within your existing workflow.* *available at*, <http://www.mckesson.com/documents/providers/interqual-connect-fact-sheet/>

<https://www.cardinalhealth.com/en/medical-affairs/continuing-education-opportunities.html>

<https://www.rbc.cardinalhealth.com/about-rbc>

Comments to proposed regulations issued under 42 CFR 402 and 403 (mandated by Section 6002 of the Patient Protection and Affordable Care Act), contained at <https://policymed.typepad.com/files/imedex-comments-to-cms-ppsa.pdf>

<https://www.cmeoutfitters.com/transfers/cm/?ID=28446>

NASEM Report (2017).

DEA's Failure to Combat Diversion Cost Lives: Results from the West Virginia Attorney General's Investigation into the DEA's Catastrophic Failure to Manage the National Drug Quota System from 2010-2016, Office of the Attorney General of West Virginia, June 4, 2020

CDC (Cent. Dis. Control. Prev.). (2014). QuickStats: rates of drug poisoning deaths involving heroin,* by selected age and racial/ethnic groups—United States, 2002 and 2011. *MMWR*, (63), 595

Resiliency Plan for Cabell County. In: Division of Addiction Sciences, ed. https://jcesom.marshall.edu/media/58477/2020_cabell-county-resiliency-plan_final.pdf2020

Transcript of 5/8/2018 Hearing of U.S. House Committee on Energy and Commerce

Plea Agreement, Case 1:07-cr-00029-JPJ (W.D. Va.).

American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders : DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association; 2013.

"Abuse of Drug 'Getting Worse,'" Richmond Times Dispatch (Virginia) May 18, 2001

"Drug's Abuse Concerns FDA," Richmond Times Dispatch (Virginia) March 23, 2001

Drug is in county, but not yet widely used,"" Intelligencer Journal (Lancaster, PA), January 4, 2001"

"More Overdose Deaths Blamed on Painkiller." Columbus Dispatch (Ohio), January 6, 2002

"No Matter What you Call It, It's Still Just Plain Ol' Dope," Richmond Times Dispatch (Virginia) March 18, 2001

"Oxycontin: It's Use and Abuse," Transcript of the Hearing Before the Subcommittee on Energy and Commerce, House of Representatives, One Hundred and Seventh Congress, First Session, August 28, 2001

"Painkiller Stirs Concern, Debate: Meeting on Key Brand is Today," Richmond Times Dispatch (Virginia) March 1, 2001

"Pilfering Pills." Columbus Dispatch (Ohio), July 18, 2001

"Purdue Fredrick Pleads Guilty in Oxycontin Case," Reuters, May 10, 2007 at
<https://www.reuters.com/article/us-oxycontin-misbranding/purdue-frederick-pleads-guilty-in-oxycontin-case-idUSWBT00695020070510>

"Sen. Warner Calls for Drug Hearing," Richmond Times Dispatch (Virginia) August 1, 2001

"The Alchemy of Oxycontin," July 29, 2001 (N.Y. Times) at
<https://www.nytimes.com/2001/07/29/magazine/the-alchemy-of-oxycontin.html>

"Hillbilly Heroin' Holds Appalachia in Its Grip of Death and Addiction," June 17, 2001 at
<https://www.latimes.com/archives/la-xpm-2001-jun-17-mn-11349-story.html>

Tom Breen, Hydrocodone Abuse on the Rise in Appalachia, ASSOCIATED PRESS reprinted in WASH. POST, Aug. 21, 2007, <http://www.washingtonpost.com/wp-dyn/content/article/2007/08/21/AR2007082100146.html>

2012 Administrative Memorandum of Agreement entered into between DEA and Cardinal Health

20150824_HMO_Huntington Mayor Strategic Plan.pdf

20170500_HMO_2017 two-year Strategic Plan.pdf

U.S. DEP'T OF JUSTICE OFFICE OF INSPECTOR GEN., REVIEW OF THE DRUG ENFORCEMENT ADMINISTRATION'S INVESTIGATIONS OF THE DIVERSION OF CONTROLLED PHARMACEUTICALS (Sept. 2002) previously available at <https://oig.justice.gov/reports/DEA/e0210/final.pdf>

20180900_DEA DEA Strategy Char-Huntington.pdf

20200100_Huntington Resiliency Plan.pdf

28 Deaths Linked to Drug: Oxycontin Plagues Southwest Virginia, " Richmond Times Dispatch (Virginia) February 9, 200

Administrative Memorandum of Agreement between DEA and Mallinckrodt, July 10, 2017.
<https://www.justice.gov/usao-edmi/press-release/file/986026/download/>

American Pain Foundation. "Treatment Options: A Guide for People Living with Pain" sponsored by Cephalon and Purdue. 2007

AmerisourceBergen Corporation, AmerisourceBergen Signs Agreement with DEA Leading to Reinstatement of its Orlando Distribution Center's Suspended License to Distribute Controlled Substances, June 22, 2007, available at <http://investor.amerisourcebergen.com/news-releases/news-release-details/amerisourcebergen-signs-agreement-dea-leading-reinstatement-its> (last visited March 11, 2019)

AmerisourceBergen purchased Imedex on May 4, 2010, and the "equity and enterprise" price was \$16 million. Imedex had calendar 2003 revenues of approximately \$11 million.

<https://investor.amerisourcebergen.com/news/news-details/2004/AmerisourceBergen-Acquires-Imedex-Inc-AmerisourceBergen-Adds-Accredited-Physician-Education-Services/default.aspx>

Apr. 2020 WV Opioid-Involved Deaths and Related Harms

Article: Current Navigation Points in Drug Diversion Law: Hidden Rocks in Shallow, Murky, Drug-Infested Waters, 101 Marq. L. Rev. 333, 347 (2017)

August 28, 2001; "A Painful Abuse; Addicts' use hurts legitimate patients, too." Columbus Dispatch (Ohio), October 2, 2001

CAH to Cease Distribution from Florida Facility.pdf

CAH_DEA Order_ from Auburn, Wash. Facility.pdf

CAH_DEA_Lakeland_FL_12DEAPR.pdf

Campbell JN. 1996. APS 1995 presidential address. Pain Forum 5:85–88

Cardinal Health Inc. agrees to pay \$34 million.pdf

CDC Vital Statistics WONDER database

CDC. CDC WONDER. Multiple Cause of Death Data. Available at <https://wonder.cdc.gov/mcd.html>

Centers for Disease Control and Prevention (CDC). Vital signs: Overdoses of prescription opioid pain relievers and other drugs among women—United States, 1999–2010. MMWR Morb Mortal Wkly Rep 2013;62:537–542

Centers for Disease Control and Prevention, Data Brief 294. Drug Overdose Deaths in the United States, 1999- 2016, available at https://www.cdc.gov/nchs/data/databriefs/db294_table.pdf#page=4

Centers for Disease Control and Prevention, Data Brief 294. Drug Overdose Deaths in the United States, 1999- 2016, available at https://www.cdc.gov/nchs/data/databriefs/db294_table.pdf#page=4

Centers for Disease Control and Prevention, Drug Overdose Deaths in the United States, 1999-2017, NCHS Data Brief (Nov. 2008) available at <https://www.cdc.gov/nchs/data/databriefs/db329-h.pdf>

Sullivan, Tom, *Change Healthcare buys National Decision Support Company*, Healthcare IT News (January 18, 2018) (Available at <https://www.healthcareitnews.com/news/change-healthcare-buys-national-decision-support-company>).

Business Wire, *Change Healthcare Inc. Announces the Completion of Split-Off of McKesson's Ownership Interest* (March 10, 2020) (Available at <https://www.businesswire.com/news/home/20200310005594/en/Change-Healthcare-Announces-Completion-Split-Off-McKesson%20%99s-Ownership>).

De Lombaerde, Geert, *Change McKesson Division Joining Forces*, Nashville Post (June 28, 2016) (Available at <https://www.nashvillepost.com/business/health-care/information-technology/article/20826776/change-mckesson-division-joining-forces>).

UChicago News, *Charles M. Jacobs health care pioneer and creative force in the arts 1933-2010* (November 15, 2010) (Available at <https://news.uchicago.edu/story/charles-m-jacobs-health-care-pioneer-and-creative-force-arts-1933-2010>).

Chen LH, HedegaardH, WarnerM. 2014. Drug-Poisoning Deaths Involving Opioid Analgesics: United States, 1999–2011. NCHS Data Brief No. 166. Hyattsville, MD: Natl. Cent. Health Stat.

City of Solutions - Huntington, WV (26 Sept 2019).pdf

Business Wire, *CMS to Continue Use of InterQual Criteria* (December 19, 2016) (Available at <https://www.businesswire.com/news/home/20161219005102/en/CMS-Continue-InterQual-Criteria>).

Healthcare Innovation, *CMS to use McKesson's InterQual Criteria to support Medicare initiatives* (September 30, 2011) (Available at <https://www.hcinnovationgroup.com/home/article/13004150/cms-to-use-mckessons-interqual-criteria-to-support-medicare-initiatives>).

Tahan, Hussein M. and Teresa M. Treiger, *CMSA Core Curriculum for Case Management* (3rd edition, 2016).

Combating the Opioid Epidemic: Examining Concerns About Distribution and Diversion: Hearing Before the Subcomm. on Oversight and Investigations of the H. Comm. on Energy and Commerce, 115th Cong., 49-50 (2018) available at <https://docs.house.gov/meetings/IF/IF02/20180508/108260/HHRG-115-IF02-Transcript-20180508.pdf>

Commonwealth of Massachusetts v. Purdue Pharma L.P., et al., No. 1884-cv-01808 (Sup. Ct. Mass.)

Congressional Report at 23;Citing Centers for Disease Control and Prevention, Drug Overdose Deaths in the United States, 1999-2017, NCHS Data Brief (Nov. 2008) available at <https://www.cdc.gov/nchs/data/databriefs/db329-h.pdf>

Congressional Report at 6;
https://www.opendatanetwork.com/entity/0400000US54/West_Virginia/demographics.population.count?year=2018

Copy of Order available at https://www.govinfo.gov/content/pkg/USCOURTS-dcd-1_12-cv-00185/pdf/USCOURTS-dcd-1_12-cv-00185-0.pdf (last visited March 19, 2019)

Courtwright DT. 2001. Dark Paradise: A History of Opiate Addiction in America. Cambridge, MA: Harvard Univ. Press. Revis. Ed

Dai Z, Abate MA, Smith GS, Kraner JC, Mock AR. Fentanyl and fentanyl-analog involvement in drug-related deaths. *Drug Alcohol Depend.* 2019;196:1-8

DEA. Order to Show Cause and Immediate Suspension of Registration. In the matter of Walgreen Co., September 13, 2012. Pl. 3924. www.dea.gov/divisions/mia/2013/mia061113_appendix.pdf

Department of Justice. Rite Aid corporation and subsidiaries agree to pay \$5 million in civil penalties to resolve violations in eight states of the Controlled Substances Act (press release). Washington, DC: United States Department of Justice, January 12, 2009. <https://www.justice.gov/opa/pr/rite-aid-corporation-and-subsidiaries-agree-pay-5-million-civil-penalties-resolve-violations>

Department of Justice. Rite Aid pays \$834,200 settlement for alleged Controlled Substances Act violations in Los Angeles (press release). Los Angeles, CA: Drug Enforcement Administration, March 9, 2017. <https://www.dea.gov/press-releases/2017/03/09/rite-aid-pays-834200-settlement-alleged-controlled-substances-act>

Medina JL, Diamond S. 1977. Drug dependency in patients with chronic headache. *Headache* 17:12–14

Drug Market Analysis 2008: Appalachia High Intensity Drug Trafficking Area, a Report by DOJ National Intelligence Center (2008)

Fauber J. 2012. Painkiller boom fueled by networking: doctors, researchers with financial ties to drug makers set stage for surge in prescriptions. *Milwaukee-Wisconsin Journal Sentinel*, Feb. 18, p. A1

FDA Analysis of Long-Term Trends in Prescription Opioid Analgesic Products: Quantity, Sales, and Price Trends, FDA (Mar. 1, 2018)
<https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM598899.pdf>

FINAL - West Virginia 2020_2022 Council Substance Use Plan_January 20, 2020 (as filed).pdf

Hospitalization Costs for People undergoing surgery

http://data.ap.org/projects/2016/cpi_ap_opioids/indexcpiap.html

<https://aspe.hhs.gov/basic-report/opioid-abuse-us-and-hhs-actions-address-opioid-drug-related-overdoses-and-deaths>

<https://ct1.medstarhealth.org/content/uploads/sites/43/2017/06/Pain-Management-Injections-07-17.pdf>

https://mediproviders.anthem.com/Documents/KYKY_CAID_MP_CUMG_Jan2018.pdf

https://providers.amerigroup.com/Documents/KSKS_CAID_UMGuidelines.pdf

<https://www.amerihealthcaritasla.com/global/assets/pdf/provider/clinical-policies/ccp1098-2004-spinal-cord-stimulators-chronic-pain.pdf>

<https://www.amerihealthcaritasnh.com/global/assets/pdf/provider/clinical-policies/ccp1093-2002-intrathecal-opioid-therapy-chronic-pain.pdf>

https://www.businesswire.com/news/home/20040408_240994388_legacyID/en/McKessons-Newest-InterQual-Release-Advances-Care-Management

<https://www.changehealthcare.com/solutions/clinical-decision-support/interqual>

<https://www.cnbc.com/id/18591525>

<https://www.drugstorenews.com/pharmacy/nacds-elects-board-directors/> (representatives of McKesson and Cardinal Health elected to NACDS Board of Directors in 2009)

<https://www.fda.gov/news-events/press-announcements/fda-requests-removal-opana-er-risks-related-abuse>

<https://www.justice.gov/archive/opa/pr/2008/September/08-civ-860.html>

<https://www.mckesson.com/About-McKesson/Newsroom/Press-Releases/2020/McKesson-Completes-Split-Off-Interest-Change-Healthcare/>

<https://www.molinahealthcare.com/providers/wa/medicaid/resource/PDF/implanted-intrathecalpain-mcp160.pdf>

<https://www.nacds.org/membership/directories/associate-companies/>

<https://www.nytimes.com/2007/05/10/business/11drug-web.html>

<https://www.reuters.com/article/idUSIN20070403082428ABC20070403>

<https://www.reuters.com/article/us-oxycontin-misbranding/purdue-frederick-pleads-guilty-in-oxycontin-case-idUSWBT00695020070510>

<https://www.streetinsider.com/Mergers+and+Acquisitions/AmerisourceBergen%28ABC%29+Acquires+Xcenda+LLC+for+%2425M/1965781.html>

<https://www.supermarketnews.com/executivechanges/wakefern-s-chris-lane-named-nacds-chairman> (representatives of McKesson and Cardinal Health elected to NACDS Board of Directors in 2019) (board of director membership is a three year term)

Hughes, A., Williams, M. R., Lipari, R. N., Bose, J., Copello, E. A. P., & Kroutil, L. A. Prescription drug use and misuse in the United States: Results from the 2015 National Survey on Drug Use and Health. NSDUH

Int'l Narcotics Control Bd., Narcotic Drugs: Estimated World Requirements for 2018; Statistics for 2016, 36 (2017) available at https://www.incb.org/documents/Narcotic-Drugs/TechnicalPublications/2017/Narcotic_drugs_technical_publication_2017.pdf

McKesson Corporation. (2017, January 5). Retrieved from <https://www.mckesson.com/about-mckesson/newsroom/press-releases/2017/mckesson-and-change-healthcare-announce-new-company-named-change-healthcare/>

McKesson Corporation. (2017, March 2). Retrieved from <https://www.mckesson.com/about-mckesson/newsroom/press-releases/2017/mckesson-and-change-healthcare-complete-the-creation-of-new-healthcare-information-technology-company/>

Business Wire, Inc. (2017, January 17). McKesson Brings InterQual Criteria to the Cloud. Retrieved from <https://www.businesswire.com/news/home/20170117005093/en/McKesson-Brings-InterQual-Criteria-Cloud>

Business Wire, Inc. (2020, March 10). Change Healthcare Inc. Announces the Completion of Split-Off of McKesson's Ownership Interest. Retrieved from <https://www.businesswire.com/news/home/20200310005594/en/Change-Healthcare-Announces-Completion-Split-Off-McKesson's-Ownership>

McKesson Corporation. (2019, June 27). Retrieved from <https://www.mckesson.com/about-mckesson/newsroom/press-releases/2019/mckesson-statement-change-healthcare-ipo/>

McKesson Corporation. (2020, February 10). Retrieved from <https://www.mckesson.com/About-McKesson/Newsroom/Press-Releases/2020/McKesson-Split-Off-Interest-Change-Healthcare/>

T. S. (2017, February 20). McKesson previews early version of InterQual Auto Review at HIMSS17. Retrieved from <https://www.healthcareitnews.com/news/mckesson-previews-every-version-interqual-auto-review-himss17>

McKesson, McKesson Health Solutions (2016) (Available at http://mms.businesswire.com/media/20160919005467/en/545063/1/MHS_Product_Brochure_Sept_2016.pdf?download=1)

Muhuri PK, Gfroerer JC, Davies MC. 2013. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Rev. Aug.: <http://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.html>

Nashville-based Change Healthcare files for \$100 million IPO - MedCity News

National Institute on Drug Abuse (NIDA), West Virginia Opioid Summary, June 13, 2019, available at <https://www.drugabuse.gov/opioid-summaries-by-state/west-virginia-opioid-summary>

Nearly 500 Organizations License InterQual in Six-Month Period _ Business Wire

McKesson HBO, Inc. (2000). Annual Report – Fiscal Year 2000.
http://www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2000.pdf

McKesson HBOC, Inc. (2001). United States Securities and Exchange Commission form 10-K. Retrieved from https://www.annualreports.com/HostedData/AnnualReportArchive/m/NYSE_MCK_2001.pdf

McKesson Corporation (2002). United States Securities and Exchange Commission form 10-K.
http://www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2002.pdf

McKesson Corporation (2003). United States Securities and Exchange Commission form 10-K.
http://www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2003.pdf

McKesson Corporation (2004). United States Securities and Exchange Commission form 10-K.
http://www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2004.pdf

McKesson Corporation (2005). United States Securities and Exchange Commission form 10-K.
www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2005.pdf

McKesson Corporation (2006). United States Securities and Exchange Commission form 10-K.
www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2006.pdf

McKesson Corporation (2007). United States Securities and Exchange Commission form 10-K.
www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2007.pdf

McKesson Corporation. (2008) Annual Report – Fiscal Year 2008.
[https://www.annualreports.com/HostedData/AnnualReportArchive/m/NYSE_MCK_2008.pdf](http://www.annualreports.com/HostedData/AnnualReportArchive/m/NYSE_MCK_2008.pdf)

McKesson Corporation. (2009) Annual Report – Fiscal Year Ended March 31, 2009.
http://www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2009.pdf

McKesson Corporation (2010). United States Securities and Exchange Commission form 10-K.
http://www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2010.pdf

McKesson Corporation. (2011) Annual Report – Fiscal Year Ended March 31, 2011.
http://www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2011.pdf

McKesson Corporation (2012). United States Securities and Exchange Commission form 10-K.
http://www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2012.pdf

McKesson Corporation (2013). United States Securities and Exchange Commission form 10-K.
www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2013.pdf

McKesson Corporation. (2014) Annual Report – Fiscal Year Ended March 31, 2014.
http://www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2014.pdf

McKesson Corporation. (2015) Annual Report – Fiscal Year Ended March 31, 2015.
www.annualreports.co.uk/HostedData/AnnualReportArchive/m/NYSE_MCK_2015.pdf

McKesson Corporation. (2016). 2016 Annual Report.
https://www.annualreports.com/HostedData/AnnualReportArchive/m/NYSE_MCK_2016.pdf

McKesson Corporation. (2017) Annual Report – Fiscal Year Ended March 31, 2017.
http://www.annualreports.com/HostedData/AnnualReportArchive/m/NYSE_MCK_2017.pdf

Press Release, Centers for Disease Control and Prevention, CDC Director’s Media Statement on U.S. Life Expectancy (Nov. 29, 2018) available at <https://www.cdc.gov/media/releases/2018/s1129-US-life-expectancy.html>

Proposed Opioid Response Plan for the State of West Virginia 1 10 18.pdf

Report by the United States House of Representatives Energy and Commerce Committee, Red Flags and Warning Signs Ignored: Opioid Distribution and Enforcement Concerns in West Virginia, December 19, 2018 at 25. (hereinafter “Congressional Report”)

Report by the United States House of Representatives Energy and Commerce Committee, Red Flags and Warning Signs Ignored: Opioid Distribution and Enforcement Concerns in West Virginia, December 19, 2018 at 6. (hereinafter “Congressional Report”)

SAMHSA (Subst. Abuse Ment. Health Serv. Adm.). 2013. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. DHHS Publ. No. SMA 13-4760, DAWN Ser. D-39. Rockville, MD: SAMHSA

SAMHSA (Subst. AbuseMent. Health Serv. Adm.). 2010. Center for BehavioralHealth Statistics and Quality. Treatment Episode Data Set (TEDS): 2007. Discharges from Substance Abuse Treatment Services. DASIS Ser.: S-51, HHS Publ. No. (SMA) 10-4479. Rockville, MD: SAMHSA

SAMHSA (Subst. AbuseMent. Health Serv. Adm.). 2013. Center for BehavioralHealth Statistics and Quality. Treatment Episode Data Set (TEDS): 2001–2011. National Admissions to Substance Abuse Treatment Services. BHSIS Ser. S-65, DHHS Publ. No. SMA 13-4772. Rockville, MD: SAMHSA

Settlement and Memorandum of Agreement between Walgreens and DEA, June 11, 2013.
<https://www.wthr.com/sites/wthr.com/files/archive/WalgreensMOA.pdf>

SHADAC analysis of U.S. Drug Enforcement Agency's Automated Reports and Consolidated Ordering System (ARCOS) Retail Drug Summary Reports. State Health Compare, SHADAC, University of Minnesota, statehealthcompare.shadac.org, Accessed July 28, 2020

Shares of Change Healthcare Inc. to hit Nasdaq - Nashville Business Journal

Tom Breen, Hydrocodone Abuse on the Rise in Appalachia, ASSOCIATED PRESS reprinted in WASH. POST, Aug. 21, 2007, <http://www.washingtonpost.com/wp-dyn/content/article/2007/08/21/AR2007082100146.html>

United States Attorney's Office, Middle District of Florida. (December 23, 2016) United States Reaches \$34 Million Settlement with Cardinal Health for Civil Penalties Under the Controlled Substances Act [Press Release]. Available at <https://www.justice.gov/usao-mdfl/pr/united-states-reaches-34-million-settlement-cardinal-health-civil-penalties-under>

United States Department of Justice National Drug Intelligence Center Report, Drug Market Analysis 2008: Appalachia High Intensity Drug Trafficking Area (2008)

United States Department of Justice, "Information Bulletin: Oxycontin Diversion and Abuse," Product No. 2001-L0424-001 (January 2001)

United States Department of Justice, "Information Bulletin: Oxycontin Diversion and Abuse," Product No. 2001-L0424-001 (January 2001); US Department of Justice, Drug Enforcement Administration, "Alert: Working to Prevent the Diversion and Abuse of OxyContin," July 2001

United States Department of Justice, "Information Bulletin: Oxycontin Diversion and Abuse," Product No. Product No. 2004-L0424-017 (August 2004)

United States Department of Justice. (January 17, 2017) McKesson Agrees to Pay record \$150 Million settlement for Failure to Report Suspicious Orders of Pharmaceutical Drugs [Press Release]. Available at <https://www.justice.gov/opa/pr/mckesson-agrees-pay-record-150-million-settlement-failure-report-suspicious-orders>

United States District Attorney's Office, District of Massachusetts. (June 30, 2016) CVS to Pay \$3.5 Million to Resolve Allegations that Pharmacists Filled Fake Prescriptions [Press Release]. Available at <https://www.justice.gov/usao-ma/pr/cvs-pay-35-million-resolve-allegations-pharmacists-filled-fake-prescriptions> (last visited March 19, 2019)

United States Governmental Accountability Office, Report to Congressional Requesters, "Prescription Drugs: Oxycontin Abuse and Diversion and Efforts to Address the Problem," GAO-04-110 (December 2003)

US Department of Justice, Drug Enforcement Administration, "Alert: Working to Prevent the Diversion and Abuse of OxyContin," July 2001

US GAO (Gen. Account. Off.). OxyContin Abuse and Diversion and Efforts to Address the Problem. GAO-04-110. Washington, DC: GAO. <http://www.gao.gov/new.items/d04110.pdf>

US Reaches \$34 M. Settlement With CAH DOJ.pdf

W. Va. Dep't of Health and Human Res., 2016 West Virginia Overdose Fatality Analysis: Healthcare Systems Utilization, Risk Factors, and Opportunities for Intervention, at 9, Dec. 20, 2017 available at https://dhhr.wv.gov/bph/Documents/ODCP%20Reports%202017/2016%20West%20Virginia%20Overdose%20Fatality%20Analysis_004302018.pdf

"West Virginia Board of Pharmacy, Prescription Opioid Problematic Prescribing

Indicators County Report: Cabell County, October 2017

West Virginia Board of Pharmacy. Prescription Opioid Problematic Prescribing Indicators County Report: Cabell County. Charleston, WV: West Virginia Department of Health and Human Resources, Bureau for Public Health; October, 2017. Available at https://helpandhopewv.org/docs/PFS_County_Reports/Cabell_PfS%20County%20Reports_Final.pdf

World Health Organization. WHO good distribution practices for pharmaceutical products (Annex 5). WHO Technical Report Series, No. 957, 2010

Written Statement of Steven H. Collis Before Subcommittee on Oversight and Investigations Committee
5.8.18

Produced Documents:

ABDCMDL00002126	CAH_MDL2804_02959471
ABDCMDL00002128	CAH_MDL2804_03334629
ABDCMDL00253869	ABDCMDL00402594.pdf
ABDCMDL00264245	ABDCMDL00477846.pdf
ABDCMDL00269293	ABDCMDL00478320.pdf
ABDCMDL00269293.pdf	ABDCMDL00569571
ABDCMDL00269301	ABDCMDL03829334
ABDCMDL00269383	ABDCMDL03830243
ABDCMDL00269383.pdf	ABDCMDL04744324
ABDCMDL00274035.pdf	ABDCMDL049400319756
ABDCMDL00274105.pdf	ABDCMDL05797659_image.pdf
ABDCMDL00278153.pdf	ABDCMDL08366648
ABDCMDL00278212.pdf	ABDC-STCT000066281
ABDCMDL00279854	ABDC-STCT001978452
ABDCMDL00279854.pdf	ABDC-STCT001978452
ABDCMDL00280974.pdf	ABDC-STCT002094982
ABDCMDL00282490.pdf	ABDC-STCT002212379
ABDCMDL00288483	ABDC-STCT002251040
ABDCMDL00288484	ABDC-STCT002251040
ABDCMDL00301214.pdf	ABDC-WVFED00018369
ABDCMDL00320055	JAN-MS-00311338.
ABDCMDL00320057	ABDC-WVFED00018369
ABDCMDL00320059	ABDC-WVFED00018369
ABDCMDL00320063	ABDC-WVFED00073464
ABDCMDL00320064	ABDC-WVFED00073465
ABDCMDL00320065	Acquired_Actavis_00368068
ABDCMDL00320068	Acquired_Actavis_00368068
ABDCMDL00320068	Acquired_Actavis_00369838.pdf
ABDCMDL00323116	Acquired_Actavis_00379710
ABDCMDL00323380	Acquired_Actavis_00447129_image
ABDCMDL00323380	Acquired_Actavis_00607429
ABDCMDL00333083.pdf	Acquired_Actavis_00669723
ABDCMDL00354657	Acquired-Actavis_01170746

ABDCMDL00359830	ACTAVIS0220239
ABDCMDL00360399	ACTAVIS0302886
ABDCMDL00365073	ACTAVIS0600353
ABDCMDL00365074	ACTAVIS0600359
ABDCMDL00374353	ACTAVIS0622787
ABDCMDL00375084	ACTAVIS0622788
ABDCMDL00378493.pdf	ALLERGAN_MDL_00000044
ABDCMDL00383869.pdf	ALLERGAN_MDL_00019229
ABDCMDL00397547.pdf	ALLERGAN_MDL_01115961
ABDCMDL00398316.pdf	ALLERGAN_MDL_01246018_image
ABDCMDL00398334.pdf	ALLERGAN_MDL_01246020_image
ABDCMDL00398338.pdf	ALLERGAN_MDL_02467796.pdf
ABDCMDL00399735.pdf	ALLERGAN_MDL_02495818
ABDCMDL00400594	CAH_ALASKA_00112308
ACTAVIS0600353	ABDCMDL00250024
ACTAVIS0600362	JAN-MS-00785241
ACTAVIS0623776	MCKMDL00353261
ALLERGAN_MDL_00000042	MCKMDL00353308
ALLERGAN_MDL_00016971	MCKMDL00459598.
ALLERGAN_MDL_00684866	MCKMDL00459601.
CAH_DEPO_MONE_OH_0000285	CAH_MDL2804_00134871
CAH_MDL_PRIORPROD DEA07_00135433.pdf	CAH_MDL2804_00135203.pdf
CAH_MDL_PRIORPROD DEA07_00318789.pdf	CAH_MDL2804_00225017.pdf
CAH_MDL_PRIORPROD DEA07_00827893.pdf	CAH_MDL2804_00228327.pdf
CAH_MDL_PRIORPROD DEA07_00837645.pdf	CAH_MDL2804_00722960.pdf
CAH_MDL_PRIORPROD DEA07_00842131.pdf	CAH_MDL2804_00865762.pdf
CAH_MDL_PRIORPROD DEA07_00854208	CAH_MDL2804_00879572.pdf
CAH_MDL_PRIORPROD DEA07_00869965.pdf	CAH_MDL2804_01103874.pdf
CAH_MDL_PRIORPROD DEA07_00884470.pdf	CAH_MDL2804_01384291_image
CAH_MDL_PRIORPROD DEA07_00968964.pdf	CAH_MDL2804_01388616.pdf
CAH_MDL_PRIORPROD DEA07_01052516.pdf	CAH_MDL2804_01521354_image
CAH_MDL_PRIORPROD DEA07_01053067.pdf	CAH_MDL2804_01530076.pdf
CAH_MDL_PRIORPROD DEA07_01181262.pdf	CAH_MDL2804_02100389
CAH_MDL_PRIORPROD DEA07_01198345.pdf	CAH_MDL2804_02100389.pdf
CAH_MDL_PRIORPROD DEA07_02088028.pdf	CAH_MDL2804_02100431
CAH_MDL_PRIORPROD DEA12_00004212	CAH_MDL2804_02102331.pdf
CAH_MDL_PRIORPROD DEA12_00004353.pdf	CAH_MDL2804_02102518.pdf
CAH_MDL_PRIORPROD DEA12_00010978.pdf	CAH_MDL2804_02149723
CAH_MDL_PRIORPROD DEA12_00013049	CAH_MDL2804_02203353.pdf
CAH_MDL_PRIORPROD DEA12_00013056.pdf	CAH_MDL2804_02395264.pdf
CAH_MDL_PRIORPROD DEA12_00014414	CAH_MDL2804_02465982
CAH_MDL_PRIORPROD DEA12_00014414.pdf	CAH_MDL2804_02489188.pdf
CAH_MDL_PRIORPROD HOUSE_0003331.pdf	CAH_MDL2804_02879153
CAH_MDL2804_00104656	CAH_MDL2804_02959634
CAH_MDL2804_00105700.	CAH_MDL2804_02959635
CAH_MDL2804_00112004	CAH_MDL2804_03177666

CAH_MDL2804_00115420	CAH_MDL2804_03224633-03240087
CAH_MDL2804_00115420_CONFIDENTIAL	CAH_MDL2804_03250272
CAH_MDL2804_00116208.	CAH_MDL2804_03250329
CAH_MDL2804_00125969	CAH_MDL2804_03309960.pdf
CAH_MDL2804_00126300	CAH_MDL2804_03334630
CAH_MDL2804_00131705	CHHD_0253699_image
CAH_MDL2804_00131816	CHI_000272862
CAH_MDL2804_00131816_CONFIDENTIAL	CHI_000289460_image
CAH_MDL2804_00132701	CHI_001218354_image
CAH_MDL2804_00132726	CHI_002382673.pdf
CAH_MDL2804_00132780	CHI_002384877.pdf
CAH_MDL2804_00133350	CHI_002396645.pdf
CAH_MDL2804_00134146	CHI_002396754.pdf
CAH_MDL2804_00134434	CHI_002427835.pdf
CAH_MDL2804_00134451	CUYAH_001830378.pdf
CAH_MDL2804_00134451	CUYAH_015844541_image
CAH_MDL2804_00134454	CUYAH_015865492.pdf
CAH_MDL2804_00134510	CUYAH_015868739_image
CAH_MDL2804_00134869	ABDCMDL00250024.pdf
CAH_MDL2804_00134871	MCKMDL00465746
CAH_MDL2804_02955927	MCKMDL00465749
CAH_MDL2804_02959413	MCKMDL00465752
CAH_MDL2804_0330368	MCKMDL00465755
CAH_MDL2804_03303725	MCKMDL00465763
CUYAH_016502445.pdf	ENDO-OPIOID_MDL-04093787
DC00120560.pdf	ENDO-OPIOID_MDL-04093787
DC00170990.pdf	ENDO-OPIOID_MDL-04093787_image
DC00173983.pdf	ENDO-OPIOID_MDL-04097240
DEF-00076764_image	ENDO-OPIOID_MDL-04097240
DEF-17347_image	ENDO-OPIOID_MDL-04097240
E513_00052516_image	ENDO-OPIOID_MDL-04097240_image
E513_00129997	ENDO-OPIOID_MDL-04234777
END00732121	ENDO-OPIOID_MDL-04753956
ENDO_OPIOID_MDL_DEPONENT-000009487	ENDO-OPIOID_MDL-04815432_image
ENDO-CHI_LIT-00088728	ENDO-OPIOID_MDL-04815436_image
ENDO-CHI_LIT-00088728	ENDO-OPIOID_MDL-06234341
ENDO-CHI_LIT-00091622	ENDO-OR-CID-00418114
ENDO-CHI_LIT-00195910	EPI000869246
ENDO-CHI_LIT-00195910	EPI001222194
ENDO-CHI_LIT-00247966	HDA_MDL_000013887
ENDO-CHI_LIT-00294169	HDA_MDL_000013887
ENDO-CHI_LIT-00431191	HDA_MDL_000035893.pdf
ENDO-CHI_LIT-00470118	HDA_MDL_000081669
ENDO-NY-00377737	HDA_MDL_000081670
ENDO-NY-00377871	HDA_MDL_000081671
ENDO-NY-00378275	HDA_MDL_000131158

ENDO-NY-00378275	HDA_MDL_000159198
ENDO-NY-00378275_image	HDA_MDL_000159557
ENDO-OPIOID_MDL-00394248	HDA_MDL_000159563
ENDO-OPIOID_MDL-01445144	HDA_MDL_000162207
ENDO-OPIOID_MDL-01607349	HDA_MDL_000202605
ENDO-OPIOID_MDL-01623042	HDA_MDL_000218844.pdf
ENDO-OPIOID_MDL-01708869	HDS_MDL_00135664.pdf
ENDO-OPIOID_MDL-01928156	INSYS-MDL-008053958
ENDO-OPIOID_MDL-02217039	INSYS-MDL-008625863
ENDO-OPIOID_MDL-02224769	JAN-MS-00326339_image
ENDO-OPIOID_MDL-02224844	JAN-MS-00326341_image
ENDO-OPIOID_MDL-02254694	JAN-MS-00362392_image
ENDO-OPIOID_MDL-02254695	JAN-MS-00362395_image
ENDO-OPIOID_MDL-02261219	JAN-MS-00364683_image
ENDO-OPIOID_MDL-02261219	JAN-MS-00364686_image
ENDO-OPIOID_MDL-02261219_image	JAN-MS-00364689_image
ENDO-OPIOID_MDL-02261221	JAN-MS-00447221_image
ENDO-OPIOID_MDL-02261221	JAN-MS-00465772
ENDO-OPIOID_MDL-02261221_image	JAN-MS-00465772
ENDO-OPIOID_MDL-02261223	JAN-MS-00465772
ENDO-OPIOID_MDL-02261223	JAN-MS-00473789_image
ENDO-OPIOID_MDL-02261223_image	JAN-MS-00785242
JAN-MS-00814133	MCKMDL00353316.pdf
JAN-MS-00814133.pdf	MCKMDL00353368
JAN-MS-00814133.ppt	MCKMDL00353374
JAN-MS-00817084_image	MCKMDL00355349
JAN-MS-00817085_image	MCKMDL00355349.pdf
JAN-MS-00864519	MCKMDL00385864
JAN-MS-00864519.pdf	MCKMDL00385864
JAN-MS-00865180	MNK-T1_0000416504
JAN-MS-00865181	MCKMDL00407451.pdf
JAN-MS-00866310_image	MCKMDL00407451.pptx
JAN-MS-00866316_image	MCKMDL00407477
JAN-MS-01038959	MCKMDL00409048.pdf
JAN-MS-01071368	MCKMDL00409050.pdf
JAN-MS-01071368	MCKMDL00409174.pdf
JAN-MS-01071368	MCKMDL00409224.pdf
JAN-MS-01130535	PDD1502117658
JAN-MS-01136836	PDD1701098048
JAN-MS-02057431.pdf	MCKMDL00409453.pdf
JAN-MS-02057431.pptx	MCKMDL00418094.pdf
JAN-MS-03014558_Confidential	MCKMDL00448596.pdf
JAN-MS-04216373_image	MCKMDL00448596.pptx
JAN-MS-04218103_image	MCKMDL00462398
JAN-MS-04218105_image	MCKMDL00463200
JAN-MS-04227312_image	MCKMDL00463201

JAN-MS-04227313_Confidential	MCKMDL00464066
JAN-MS-04227313_slipsheet	MCKMDL00464377
JAN-MS-04227456_image	MCKMDL00465742
JAN-MS-04227457_image	MCKMDL00465744
JAN-MS-04241287	MCKMDL00465745
MCKMDL00000021	MCKMDL00465750
MCKMDL00000497.pdf	MCKMDL00465752
MCKMDL0017361605	MCKMDL00473378
MCKMDL00323776	MCKMDL00474152
MCKMDL00323776	PDD1701098054
MCKMDL00332932	MCKMDL00476776.pdf
MCKMDL00334317	PDD1701107091
MCKMDL00334324	MCKMDL00477362
MCKMDL00334328	MCKMDL00477362
MCKMDL00336347	MCKMDL00478906.pdf
MCKMDL00336347.pdf	MCKMDL00478910.pdf
MCKMDL00336347.pdf	MCKMDL00484449
MCKMDL00353262	MCKMDL00490713
MCKMDL00353266	MCKMDL00493101
MCKMDL00353277	MCKMDL00496195
MCKMDL00353279	MCKMDL00496306.pdf
MCKMDL00353282	MCKMDL00496876.pdf
MCKMDL00353305	MCKMDL00498057.pdf
MCKMDL00353307	MCKMDL00539021
MCKMDL00353316	MCKMDL00543406.pdf
MCKMDL00464368	PDD1701421278
MCKMDL00464370	PDD8801142910.
MCKMDL00464371	PKY181277693
MCKMDL00464377	PLPC028000117269
MCKMDL00464389	PPLP003451464
MCKMDL00469495	PPLPC025000149102
MCKMDL00477364	PPLPC025000149110
MCKMDL00477365	PPLPC034001107535
MCKMDL00477369	TEVA_MDL_A_12765926
MCKMDL00477373	ABDCMDL00000101.pdf
MCKMDL00477478	ABDCMDL00000377.pdf
MCKMDL00543462	ABDCMDL00000397
MCKMDL00543554.pdf	MNK_NC00016755
MCKMDL00543612	MNK_NC00016755
MCKMDL00543971.pdf	MNK_NC00016757
MCKMDL00545048.pdf	MNK_NC00028683
MCKMDL00545132.pdf	MNK_NC00251474
MCKMDL00545185.pdf	MNK-T1_0000416319
MCKMDL00545341	MNK-T1_0000443779
MCKMDL00545341.pdf	MNK-T1_0000499742
MCKMDL00546932	MNK-T1_0000499880

MCKMDL00571361	MNK-T1_0000506114.pdf
MCKMDL00587115_image	MNK-T1_0000563696.pdf
MCKMDL00591949.pdf	MNK-T1_0000641574_image
MCKMDL00610040	MNK-T1_0000823151
MCKMDL00619657.pdf	MNK-T1_0000917000
MCKMDL00619657.pptx	MNK-T1_0000990812
MCKMDL00634271.pdf	MNK-T1_0000990815
MCKMDL00649066	MNK-T1_0000990994.
MCKMDL00652315_image	MNK-T1_0001052415_image
MCKMDL00652317_image	MNK-T1_0001052416_image
MCKMDL00661483.pdf	MNK-T1_0001332076.pdf
MCKMDL00661598_image	MNK-T1_0001332076.ppt
MCKMDL00668399	MNK-T1_0001532952_image
MCKMDL00695128	MNK-T1_0002191216_image
MCKMDL00706767	MNK-T1_0002191218
MCKMDL00719205	MNK-T1_0002191218_slipsheet
MCKMDL00721366.pdf	MNK-T1_0002191219
MCKMDL00721376.pdf	MNK-T1_0002678103
MCKMDL00724395	MNK-T1_0002679132
MCKMDL00724422	MNK-T1_0002679132_slipsheet
MCKMDL00726854	MNK-T1_0003002580_image
MCKMDL00738002 (CAH license pulled).pdf	MNK-T1_0004876067_image
MCKMDL00837052	MNK-T1_0004876068_image
MCKMDL00868604.	MNK-T1_0005053501_image
MCKMDL00868605	ABDCMDL00002141.
MCKMDL01174072	MNK-T1_0005053502_image
MCKMDL01270812	MNK-T1_0005543594
MCKMDL01270814	MNK-T1_0005981734
MCKMDL01270821	MNK-T1_0006486651_image
MCKMDL01270827	MNK-T1_0006486652
MCKMDL01387750	MNK-T1_0006486652_slipsheet
MCKMDL01387750	MNK-T1_0006684264
MCKMDL01392944_image	MNK-T1_0006909534
MCKMDL01397081_image	MNK-T1_0006909538
MCKMDL01618970	MNK-T1_0007055940_image
ML00055624	MNK-T1_0007055941_image
MNK-T1_0007819281	PPLP003361649
MNK-T1-0001155124	PPLP003361918
MNK-T1-0002704863	PPLP003473213.pdf
PAK000212733	PPLP004210521
PAK000212734	PPLPC002000140782
PAK000269231	PPLPC0025000006304
PAK000269232	PPLPC0025000006305
PAK000269329	PPLPC0025000007431
PAK000269333	PPLPC0025000007432
PDD1502100590	PPLPC004000122279

PDD7024301502	PPLPC004000141887
PDD7024301502_image	PPLPC004000141888
PDD8801281191	ABDCMDL00002828
PDD9316706639	PPLPC004000142842
PKY180117283	PPLPC004000146529
PKY180255278	PPLPC004000183479.pdf
PKY180256902	PPLPC004000183541
PKY180256902	PPLPC004000245474
PKY180416642	PPLPC004000245474.pdf
PKY180771438	PPLPC004000246705
PKY18077399	PPLPC004000246708
PKY180796623	PPLPC004000248015
PKY180796623	PPLPC004000249167
PKY180796628	PPLPC004000249170
PKY180796628	PPLPC004000249170.pdf
PKY180796664	PPLPC004000256865
PKY180796664	PPLPC004000298375
PKY180796664_image.pdf	PPLPC004000365800.pdf
PKY180796666	PPLPC008000013580
PKY180796724	PPLPC008000013580
PKY180796724	PPLPC00800002138
PKY180947495	PPLPC008000022314
PKY180947495	PPLPC008000030097
PKY180947495_image.pdf	PPLPC008000031453
PKY181284712	PPLPC008000031453
PKY181715440	PPLPC008000031454
PKY183402315	PPLPC008000031454
PLTF_2804_000067826.pdf	PPLPC008000036382
PLTF_2804_000296556.pdf	PPLPC009000007590
PLTF_2804_000297160.pdf	PPLPC013000328276_image
PPLC051000235229	PPLPC017000044561
PPLCP031000302888	PPLPC017000187792.pdf
PPLP003299959	PPLPC018000902029_image
PPLP003337352	PPLPC018000902031_image
PPLP003361253	PPLPC019000518994
PPLPC004000073279	ABDCMDL00002831
PPLPC004000145999	ABDCMDL00046783.pdf
PPLPC004000235658 -PPLPC004000235659	ABDCMDL00090238.pdf
PPLPC004000235760 - PPLPC004000235761	ABDCMDL00146184.pdf
PPLPC019000518994	PPLPC31000214960
PPLPC019000874246_image	PURCHI-000742458.pdf
PPLPC019000897956_image	SUMMIT_000043050.pdf
PPLPC020000086520_image	SUMMIT_000824517.pdf
PPLPC020000086520_image	TEVA_AAMD_00619305
PPLPC020001151103	TEVA_MDL_A_00701449
PPLPC021000513550.pdf	TEVA_MDL_A_00782827

PPLPC022000184774	ABDCMDL00158927.pdf
PPLPC022000653078	TEVA_MDL_A_008025736
PPLPC022000986875	TEVA_MDL_A_00825736
PPLPC023000061302	TEVA_MDL_A_00858252_image
PPLPC024000532502_image	TEVA_MDL_A_00858257_image
PPLPC024000537803_image	TEVA_MDL_A_00858261_image
PPLPC025000149099	TEVA_MDL_A_00858300_image
PPLPC025000149100	TEVA_MDL_A_00858301
PPLPC025000149100	TEVA_MDL_A_00858301_slipsheet
PPLPC025000149102	TEVA_MDL_A_00858307_image
PPLPC025000149110	TEVA_MDL_A_00858312_image
PPLPC027000126679.pdf	TEVA_MDL_A_01060005.pdf
PPLPC028000008080	TEVA_MDL_A_01180335
PPLPC028000587023	TEVA_MDL_A_01180335
PPLPC029000022136	TEVA_MDL_A_01180335_image
PPLPC029000177585	TEVA_MDL_A_01182428
PPLPC030000271126	ABDCMDL00158927.ppt
PPLPC030000564197	ABDCMDL00159415.pdf
PPLPC031000385886	TEVA_MDL_A_01236538_image
PPLPC031000860595.pdf	TEVA_MDL_A_01307786
PPLPC031001481881	TEVA_MDL_A_01853080
PPLPC034000102543	ABDCMDL00161397.pdf
PPLPC036000091671_image	TEVA_MDL_A_01907306_image
PPLPC039000195285_image	TEVA_MDL_A_01907307
PPLPC039000672710_image	TEVA_MDL_A_01907307_slipsheet
PPLPC039000672711_CONFIDENTIAL	TEVA_MDL_A_02366619_image
PPLPC039000672711_slipsheet	TEVA_MDL_A_02366621_Confidential
PPLPC045000002603	TEVA_MDL_A_02366621_slipsheet
PPLPC045000002604	TEVA_MDL_A_02481717
PPLPC046000040434	TEVA_MDL_A_02481724
PPLPC046000062722_image	TEVA_MDL_A_02482047
PPLPC046000062729_image	TEVA_MDL_A_02482061
PPLPC046000062731_image	TEVA_MDL_A_02482064
PPLPC047000031685_image	TEVA_MDL_A_02482082
PPLPC047000031688_image	TEVA_MDL_A_02482606
PPLPC051000001178	TEVA_MDL_A_02485201
PPLPC05600009410	TEVA_MDL_A_02485506
PPLPC05600009410	TEVA_MDL_A_02485891
PPLPC05600009412	TEVA_MDL_A_02486818
PPLPC05600009413	TEVA_MDL_A_02486851
PPLPC31000214959	TEVA_MDL_A_02486863
TEVA_MDL_A_02486875	TEVA_MDL_A_03536275
TEVA_MDL_A_02487152	TEVA_MDL_A_03536515
TEVA_MDL_A_02553105_image	TEVA_MDL_A_03547843_image
TEVA_MDL_A_02674754	TEVA_MDL_A_03548111_image
TEVA_MDL_A_02722309	TEVA_MDL_A_03548120

TEVA_MDL_A_02819133_image	TEVA_MDL_A_03548120_slipsheet
TEVA_MDL_A_02819135_image	TEVA_MDL_A_03949078
TEVA_MDL_A_02819137_Highly Confidential	TEVA_MDL_A_03950295
TEVA_MDL_A_02819137_slipsheet	TEVA_MDL_A_03950296
TEVA_MDL_A_02935210	TEVA_MDL_A_06557774
TEVA_MDL_A_02935212	TEVA_MDL_A_06559377
TEVA_MDL_A_02935214	TEVA_MDL_A_06758021
TEVA_MDL_A_02935216	TEVA_MDL_A_06758021
TEVA_MDL_A_02935426	TEVA_MDL_A_06758021_image
TEVA_MDL_A_02935428	TEVA_MDL_A_06764971
TEVA_MDL_A_02935519	TEVA_MDL_A_06764971
TEVA_MDL_A_02935521	TEVA_MDL_A_06764971_image
TEVA_MDL_A_02953776	TEVA_MDL_A_06769509
TEVA_MDL_A_02953879	TEVA_MDL_A_06769509
TEVA_MDL_A_02953905	TEVA_MDL_A_06769509_image
TEVA_MDL_A_02953959_Highly Confidential	TEVA_MDL_A_06771229
TEVA_MDL_A_02953959_image	TEVA_MDL_A_06771229
TEVA_MDL_A_02953959_slipsheet	TEVA_MDL_A_06771229
TEVA_MDL_A_02955356_image	TEVA_MDL_A_06771229_image
TEVA_MDL_A_02964576_Highly Confidential	TEVA_MDL_A_06772174
TEVA_MDL_A_02964576_image	TEVA_MDL_A_06772174
TEVA_MDL_A_02964576_slipsheet	TEVA_MDL_A_06772174_image
TEVA_MDL_A_02966982	TEVA_MDL_A_06794030
TEVA_MDL_A_03010771_image	TEVA_MDL_A_06794030
TEVA_MDL_A_03010773	TEVA_MDL_A_08761194.pdf
TEVA_MDL_A_03010773	TEVA_MDL_A_08845018_image
TEVA_MDL_A_03195537_image	TEVA_MDL_A_08855370
TEVA_MDL_A_03195537_image	TEVA_MDL_A_08855370
TEVA_MDL_A_03195786_image	TEVA_MDL_A_09165501_image
TEVA_MDL_A_03195788_image	TEVA_MDL_A_09165507
TEVA_MDL_A_03195792_image	TEVA_MDL_A_09165507_slipsheet
TEVA_MDL_A_03195793_image	TEVA_MDL_A_11786072
TEVA_MDL_A_03195797_slipsheet	TEVA_MDL_A_11885794
TEVA_MDL_A_03217416_image	TEVA_MDL_A_12746422
TEVA_MDL_A_03217417_Confidential	TEVA_MDL_A_12765924
TEVA_MDL_A_03217417_slipsheet	TEVA_MDL_A_12782509
TEVA_MDL_A_03452670	TEVA_MDL_A_13494044
TEVA_MDL_A_03535304	TEVA_MDL_A_13495736
TEVA_MDL_A_03536110	US-DEA-00025656.pdf
TEVA_MDL_A_12745916.	ABDCMDL00169253
TEVA_MDL_A_12745917	ABDCMDL00169889
WAGFLDEA00000852.pdf	EPI001059511
WAGFLDEA00000872.pdf	PPLP004298301
WAGFLDEA00001733.pdf	HDA_MDL_000117003
WAGMDL00010887.pdf	PPLP003985888
WAGMDL00021425.pdf	PPLP004051807

WAGMDL00049752.pdf	PPLPC051000064077
WAGMDL00246275.pdf	EPI000066634
WAGMDL00302949.pdf	PPLP004299456
WAGMDL00303029.pdf	PPLP004065860
WAGMDL00325170.pdf	PPLP004267403
WAGMDL00386743.pdf	PPLP004267618
WAGMDL00414048.pdf	PPLPC0190012650
WAGMDL00426251.pdf	PPLPC017000798471
WAGMDL00429246.pdf	CAH_MDL2804_02505518
WAGMDL00490963.pdf	MNK-T1_0005783676-678
WAGMDL00492171.pdf	PPLPC037000008901
WAGMDL00493694.pdf	HDA_MDL_000157898.
WAGMDL00493697.pdf	HDA_MDL_000084666
WAGMDL00659270.pdf	HSI-MDL-00620224
WAGMDL00659801.pdf	HDA_MDL_000143030
WAGMDL00660331.pdf	CAH_MDL2804_01521412
WAGMDL00667936.pdf	HDA_MDL_000156499
WAGMDL00674280.pdf	HDA_MDL_000142905
WAGMDL00709395.pdf	HDA_MDL_000118385
WAGMDL00709508.pdf	HDA_MDL_000093755
WAGMDL00709510.pdf	HDA_MDL_000117145
WAGMDL00757193.pdf	HDA_MDL_000117158
WAGMDL00757790.pdf	HDA_MDL_000080421
WAGMDL00757798.pdf	CAH_MDL2804_02489188
WAGMDL00774715.pdf	HDA_MDL_000155886
WAGMDL00845867_image	HDA_MDL_000155930
WAGMDL00845878 (A-5)	HDA_MDL_000081415
PPLPC019000346516	HDA_MDL_000087762
PPLPC034000451465	MCKMDL00586952
PPLP004469304	CAH_MDL2804_01505341
PPLP004473046	HAD_MDL_000087734
PPLP004473318	HDA_MDL_000087806
PPLP004437208	CAH_MDL2804_03388866
PPLP004469394	MCKMDL00332932
PPLPC023000285327	MCKMDL00543610
PPLP004473227	US-DEA-00000352
PPLPC018000502666	US-DEA-00000369
PPLPC020000496773	US-DEA-00000371
MCKMDL00634412	US-DEA-00000147
PPLP004472303	US-DEA-00000144
PPLPC004000310913	CVS-MDLT1-000060822
ABDCMDL00301700	CVS-MDLT1-00060907
PPLP004473294	CVS-MDLT1-000060796
PPLPC020000558069	CVS-MDLT1-000099702
PPLPC022000513320	CVS-MDLT1-000060847
MCKMDL00575490	CVS-MDLT1-00060915

CAH_MDL2804_008795722	CVS-MDLT1-00008014
MNK-T1_0000559532	CVS-MDLT1-000076135
CAH_MDL2804_01454458	CVS-MDLT1-000060805
MCKMDL00634329	CVS-MDLT1_000060830
MCKMDL00634329	PPLP004474439-440
MCKMDL00516748	MCKMDL00536290
MCKMDL00827928	MCKMDL00536290
MCKMDL01940693	CAH_MDL2804_00851292
MCKMDL00450972	PPLPC053000021255
AHIDTA_0404-425	PPLPC018000200323
AHIDTA_0972-1014	PPLP00438536
AHIDTA_0905-947	PPLPC004000182848
AHIDTA_1168-1215	ABDCMDL00364944
PPLPC031000256122	CAH_MDL2804_0087957
ABDCMDL00170213	PPLPC053000039688
ABDCMDL00280699	HDS_MDL_00086622
ABDCMDL04476169	PPLPC021000249399
PPLP004272094	HUNT_00286731
MNK-T1_0000115216	HUNT_00029464
ACTAVIS0623268	CCDS_0044668
AAFP0001084	CCDS_0029884
AAPA_00000594	HUNT_00263760
ENDO-OPIOID_MDL-02821120	CCDS_0028875
PPLPC029000236513	CCIRC_0303373
MAL-MI000157630	CCIRC_0303340
ALLERGAN_MDL_02461021	HUNT_00730154
ACTAVIS0620574	CAH_ALASKA_00190590
ACTAVIS0623269	ABDCMDL08307607
ACTAVIS0623266	MCKMDL00557252
EPI000888887	CAH_MDL2804_01493700
ACTAVIS0620245	
ABDCMDL03830512	
MCKMDL00354776	
MCKMDL00497923	
MCKMDL00535683	
MCKMDL00541773	
ABDCMDL01610737	
ABDCMDL01691017	
ABDCMDL07229938	
CAH_MDL_PRIORPROD_DEA07_00053986	
CAH_MDL_PRIORPROD_DEA07_00509337	
CAH_MDL2804_01942269	
MCKMDL00827928	

MDL 2804 Deposition Transcripts:

Canafax, Raymond	Welch, Crystal
Dial, Hank	Arthur, Scott
Gray, John	Hartle, Nathan
Hazewski, Edward	Hazelett, Tim
Hunter, Paul	Saper, Joel
Johnson, Rocky	McComas, Thomas
Leftwich, Nicholas	Williams, Steve
Napier, Kathleen	Fri, Perry
Norton, Rita	Jacobs, Garret
Preece, Craig	Lemley, Scott
Rader, Jan	Kelly, Patrick
Rosen, Burt	Merry, Gordon
Runyon, Deron	Brown, Vic
Smith, Phyllis	Painter, Sue Ann
Sobonya, Kelli	Adams, Doug
Thompson, Beth	Adkins, Elizabeth
Zerkle, Charles	Zimmerman, Chris

Deposition Exhibits:

Rosen-001	Saper-001
Rosen-002	Saper-002
Rosen-003	Saper-003
Rosen-004	Saper-004
Rosen-005	Saper-005
Rosen-006	Saper-006
Rosen-007	Saper-007
Rosen-008	Gray-002
Rosen-009	Gray-003
Rosen-010	Gray-004
Rosen-011	Gray-005
Rosen-012	Gray-006
Rosen-013	Gray-008
Rosen-014	Gray-009
Rosen-015	Gray-010
Rosen-016	Gray-013
Rosen-017	Gray-014
Rosen-018	Gray-016
Rosen-019	Gray-017
Rosen-020	Gray-019
Rosen-021	Gray-021
Rosen-022	Gray-024
Rosen-023	Gray-025
Rosen-024	Gray-026
Rosen-025	Gray-028

Rosen-026	Gray-029
Rosen-027	Gray-030
Rosen-028	Gray-031
Rosen-029	Gray-034
Rosen-030	Gray-035
Rosen-031	Gray-036
Rosen-032	Gray-037
Rosen-033	Gray-040
Rosen-034	Gray-043
Rosen-035	Gray-045
Rosen-036	Gray-047
Rosen-037	Gray-048
Rosen-038	Gray-049
Rosen-039	Gray-050
Rosen-040	Gray-052
Rosen-041	Gray-054
Rosen-042	Gray-055
Rosen-043	Gray-057
Rosen-044	Gray-059
Rosen-045	Gray-063
Rosen-046	Gray-064
Rosen-047	Gray-065
Rosen-048	Gray-074
Gray-075	Gray-079
Gray-078	